What Is Necrobiosis Lipoidica?

Necrobiosis Lipoidica, historically termed necrobiosis lipoidica diabeticorum, is a chronic granulomatous skin disorder that presents as well-demarcated, waxy, yellowish-brown plaques predominantly on the anterior shins. While first described in patients with diabetes mellitus, the condition can also affect nondiabetic individuals, albeit less frequently. The clinical course is typically indolent, often persisting for years, and carries significant cosmetic and functional morbidity when ulceration develops.

The classic lesion begins as small, red-brown papules that gradually enlarge and coalesce into oval or irregular plaques with a shiny, atrophic central zone and a violaceous, slightly raised border. Telangiectasias are frequently visible on the surface, giving the lesion a distinctive appearance. The term "necrobiosis" refers to the histological finding of degenerated collagen with surrounding granulomatous inflammation, while "lipoidica" describes the lipid deposition that contributes to the characteristic yellowish hue. Ulceration occurs in 15–35% of cases, often precipitated by minor trauma, and can be painful, slow to heal, and prone to secondary infection.

Epidemiologically, necrobiosis lipoidica affects approximately 0.3–1.6% of the diabetic population, with a strong predilection for type 1 diabetes. Women are affected three times more frequently than men, and the mean age of onset is between 30 and 40 years. The condition is rare in children, though pediatric cases have been documented. Understanding the natural history and burden of this disorder is essential for clinicians managing diabetic patients with cutaneous complications.

Causes and Pathophysiology

The precise etiology of necrobiosis lipoidica remains incompletely understood, but a multifactorial pathogenesis is widely accepted. Current evidence points to three interrelated mechanisms that converge to produce the characteristic histopathological and clinical features.

Vascular Abnormalities and Microangiopathy

Microvascular disease is a hallmark of diabetes and is believed to play a central role in the development of necrobiosis lipoidica. Histopathological studies consistently demonstrate thickening of capillary basement membranes, endothelial cell swelling and proliferation, and occlusion of small vessels by fibrin thrombi. These microvascular changes impair nutritional perfusion to the dermis, creating a state of chronic ischemia that leads to collagen degeneration and necrosis. The anterior shins, which have relatively poor blood supply and are subject to repeated minor trauma, are particularly vulnerable. Doppler ultrasound and capillaroscopy studies have shown reduced blood flow in affected areas compared to adjacent normal skin, supporting the vascular hypothesis.

Immune-Mediated Inflammation

An autoimmune component is strongly suggested by several lines of evidence. Histologically, a dense perivascular and interstitial infiltrate composed of lymphocytes, histiocytes, and multinucleated giant cells is characteristic. Direct immunofluorescence studies have demonstrated deposition of immunoglobulins, complement components, and fibrinogen at the dermal-epidermal junction and around blood vessels. Additionally, some patients harbor circulating antiphospholipid antibodies, elevated levels of tumor necrosis factor-alpha (TNF-α), and abnormal lymphocyte function. The granulomatous response may be triggered by altered collagen or by antigens released from damaged endothelial cells. The strong association with type 1 diabetes, itself an autoimmune disease, further supports an immune-mediated pathogenesis.

Altered Collagen Metabolism and Glycation

Chronic hyperglycemia promotes non-enzymatic glycation of collagen and other extracellular matrix proteins. Advanced glycation end products (AGEs) accumulate in the dermis, leading to cross-linking of collagen fibers, reduced turnover, and increased susceptibility to denaturation and enzymatic degradation. This biochemical alteration is thought to contribute directly to the necrobiotic process. Furthermore, glycation of collagen alters its immunogenicity, potentially triggering the granulomatous response. Lipid deposition in the dermis, which gives the lesions their yellowish color, may result from disturbed lipid metabolism commonly seen in diabetes, including increased oxidation of low-density lipoproteins and impaired clearance of lipid debris.

Emerging research has also identified potential roles for oxidative stress, impaired angiogenesis, and dysregulation of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs). An imbalance between MMPs and TIMPs may contribute to the aberrant remodeling of extracellular matrix that characterizes the disorder. For an in-depth review of the molecular mechanisms, readers are referred to a comprehensive analysis published in Experimental Dermatology (see journal reference).

Risk Factors for Developing Necrobiosis Lipoidica in Diabetics

While necrobiosis lipoidica can affect any diabetic patient, several demographic, clinical, and behavioral factors significantly increase the likelihood of developing the condition. Identifying these risk factors is critical for early detection and preventive intervention.

Type of Diabetes

Type 1 diabetes carries a markedly higher risk than type 2 diabetes. In most case series, 60–80% of patients with necrobiosis lipoidica have type 1 diabetes, while 10–20% have type 2 diabetes, and the remainder are nondiabetic. The relative risk for type 1 versus type 2 diabetes is estimated at 3:1 to 5:1. This strong association with type 1 suggests a shared autoimmune diathesis, as type 1 diabetes is an organ-specific autoimmune disease directed against pancreatic beta cells. The presence of islet cell antibodies and other autoantibodies is more common in necrobiosis lipoidica patients with type 1 diabetes than in those without skin lesions.

Duration of Diabetes

The risk of developing necrobiosis lipoidica increases progressively with the length of time a person has lived with diabetes. Many patients develop skin lesions after 10–15 years of disease, and the cumulative incidence continues to rise thereafter. This timeline parallels the development of other diabetic microvascular complications such as retinopathy, neuropathy, and nephropathy, supporting the role of cumulative metabolic damage. In patients with type 1 diabetes, the onset of necrobiosis lipoidica may coincide with the development of other complications, making it a potential cutaneous marker of systemic microangiopathy.

Poor Glycemic Control

Elevated HbA1c levels and wide fluctuations in blood glucose are consistently associated with a greater incidence and severity of necrobiosis lipoidica. Chronic hyperglycemia accelerates collagen glycation, promotes microangiopathy, and impairs immune function, all of which contribute to lesion formation. In cohort studies, patients with HbA1c levels above 8.0% have a two- to threefold higher risk of developing necrobiosis lipoidica compared to those with tighter glycemic control. Conversely, improved glycemic control through intensive insulin therapy or continuous glucose monitoring may slow disease progression but rarely leads to complete resolution of established lesions.

Female Gender

Women are approximately three times more likely to develop necrobiosis lipoidica than men, a finding that has been consistently reproduced across different populations and geographic regions. The reason for this gender disparity remains unclear, but postulated mechanisms include hormonal influences on immune regulation, differences in microvascular reactivity, and variations in collagen metabolism. Estrogen and progesterone receptors have been identified on dermal fibroblasts and vascular endothelium, and fluctuations in hormone levels may modulate the inflammatory response and vascular permeability.

Smoking

Tobacco smoking is one of the most potent modifiable risk factors for necrobiosis lipoidica. Smoking compounds microvascular damage by inducing vasoconstriction, increasing blood viscosity, promoting endothelial dysfunction, and generating oxidative stress. Smokers with diabetes have a markedly higher risk of both developing new lesions and experiencing ulceration of existing plaques. In a case-control study, current smokers had a 3.5-fold increased odds of necrobiosis lipoidica compared to never-smokers, and the risk increased with pack-year history. Smoking cessation is consistently associated with stabilization of disease and reduced ulceration rates, making it a cornerstone of management.

Genetic Predisposition

Familial clustering of necrobiosis lipoidica has been reported, and certain HLA haplotypes may confer susceptibility. The strongest associations have been found with HLA-DR4 and HLA-DR3, the same haplotypes that are overrepresented in type 1 diabetes. This genetic overlap further links the two conditions and suggests that shared immune response genes contribute to disease pathogenesis. Genome-wide association studies are ongoing to identify additional susceptibility loci, but candidate gene approaches have also implicated polymorphisms in genes encoding TNF-α, vascular endothelial growth factor (VEGF), and matrix metalloproteinases.

Presence of Other Diabetic Complications

Patients who already have diabetic retinopathy, neuropathy, or nephropathy are significantly more likely to develop necrobiosis lipoidica. In cross-sectional studies, the prevalence of necrobiosis lipoidica is 2–4 times higher among diabetics with microvascular complications compared to those without. This suggests that the cutaneous lesions are another manifestation of systemic microangiopathy rather than an isolated phenomenon. Regular ophthalmological and renal screening in patients with necrobiosis lipoidica is therefore important, as the skin disease may herald the presence or progression of other complications.

Body Mass Index and Dyslipidemia

Obesity and dyslipidemia have been identified as independent risk factors in some studies, particularly among patients with type 2 diabetes. Elevated triglycerides and low high-density lipoprotein cholesterol levels are associated with more extensive and ulcerated disease. The mechanisms may involve increased oxidative stress, altered lipid metabolism in the dermis, and impaired wound healing. Weight reduction and lipid-lowering therapy may have a beneficial effect on disease course, though prospective trials are lacking.

For a deeper dive into the risk factors and epidemiology, refer to this comprehensive review on DermNet NZ.

Clinical Presentation and Variants

The classic presentation of necrobiosis lipoidica is on the pretibial region of both legs, with bilateral involvement occurring in 50–75% of cases. The distribution is often asymmetrical, and lesions may be solitary or multiple. The plaques are slowly progressive, sometimes remaining stable for years, and can range from 1 cm to over 20 cm in diameter. The surface is smooth, waxy, and atrophic, with a characteristic yellowish-brown color and prominent telangiectasias. The border is typically violaceous and slightly raised, representing the active inflammatory edge.

Less commonly, lesions may appear on the arms, trunk, face, or scalp, though such extra-tibial involvement is more frequent in nondiabetic patients. Atypical locations should prompt consideration of alternative diagnoses such as sarcoidosis or granuloma annulare.

Several clinical variants are recognized:

  • Ulcerated necrobiosis lipoidica – develops in up to one-third of patients, often triggered by minor trauma. Ulcers are shallow, painful, and have a sloughy base with surrounding violaceous erythema. They are prone to secondary infection and can become chronic, persisting for months to years.
  • Atrophic necrobiosis lipoidica – the plaque becomes thin, depressed, and parchment-like, with prominently visible underlying blood vessels. This variant carries a higher risk of ulceration due to the fragility of the atrophic skin.
  • Sclerotic or morpheaform – lesions show marked induration and thickening, resembling localized scleroderma (morphea). This variant may be mistaken for other fibrosing disorders and often requires biopsy for differentiation.
  • Atypical presentations – pustular, bullous, nodular, and lichenoid forms have been reported in the literature. These variants are rare but can pose diagnostic challenges.

Itching is uncommon; most patients are asymptomatic aside from the cosmetic appearance. However, when ulceration occurs, pain, tenderness, and secondary infection become the dominant clinical issues. Patients may also report a burning sensation or hypersensitivity in the affected area. The psychosocial impact of visible scarring on the lower legs should not be underestimated, as many patients experience significant distress, reduced self-esteem, and avoidance of activities that expose their legs.

Diagnosis

Diagnosis is primarily clinical, based on the characteristic location, morphology, and association with diabetes. However, because necrobiosis lipoidica can mimic other skin conditions, a skin biopsy is often necessary for confirmation, especially in atypical cases or when ulceration raises concern for malignancy.

Histopathology

Biopsy of an active lesion reveals a layered or palisading granulomatous infiltrate surrounding areas of necrobiotic collagen. The necrobiotic zones consist of degenerated, eosinophilic collagen fibers with loss of normal fibrillary architecture. Surrounding these zones is a granulomatous inflammatory infiltrate composed of histiocytes, epithelioid cells, and multinucleated giant cells. The dermis shows thickened capillaries with endothelial swelling and fibrinoid deposits within and around vessel walls. Lipid deposition can be demonstrated with special stains such as Oil Red O or Sudan black on frozen sections. The epidermis is often atrophic, with flattening of the rete ridges and a thinned stratum corneum.

Histological features may overlap with granuloma annulare and sarcoidosis, but the presence of prominent vascular changes, lipid deposition, and extensive collagen degeneration favors necrobiosis lipoidica. In ulcerated lesions, secondary changes including neutrophilic infiltration, granulation tissue, and fibrosis may obscure the diagnostic features.

Differential Diagnosis

Several other skin disorders can resemble necrobiosis lipoidica and must be excluded clinically and histologically:

  • Granuloma annulare – typically presents as annular, flesh-colored or erythematous papules and plaques on the trunk and extremities. It is often self-limiting over months to years, rarely ulcerates, and is not associated with diabetes. Histologically, granuloma annulare shows palisading granulomas with mucin deposition rather than lipid.
  • Sarcoidosis – can produce similar violaceous plaques on the lower legs, but systemic involvement (lungs, lymph nodes, eyes) is common. Histology shows non-caseating granulomas without extensive necrobiosis or vascular changes. Angiotensin-converting enzyme levels may be elevated.
  • Stasis dermatitis – typically accompanied by edema, varicose veins, hemosiderin deposition (brownish discoloration), and lipodermatosclerosis. It is not granulomatous and improves with leg elevation and compression therapy.
  • Lichen sclerosus – presents as white, atrophic, crinkled plaques often involving the genitalia and extragenital sites. Histology shows homogenized collagen with a lymphocytic infiltrate below the zone of sclerosis.
  • Basal cell carcinoma – pearly, telangiectatic lesions that can ulcerate, but are more nodular and have a rolled border. Biopsy easily distinguishes this from necrobiosis lipoidica.
  • Necrobiosis lipoidica-like lesions in systemic sclerosis – these can mimic the condition but are accompanied by sclerodactyly, Raynaud phenomenon, and other systemic features of scleroderma.

An article in the International Journal of Dermatology provides a detailed clinical and histopathological comparison of these conditions (see journal reference).

Laboratory and Imaging Studies

While not diagnostic, laboratory evaluation can support the diagnosis and identify associated conditions. Recommended tests include fasting blood glucose, HbA1c, lipid panel, and, in suspected cases, antinuclear antibody, angiotensin-converting enzyme, and antiphospholipid antibodies. In patients with ulcerated lesions, wound cultures should be obtained to guide antibiotic therapy. Doppler ultrasound of the lower extremities may be useful to assess for venous insufficiency or arterial disease that could complicate wound healing.

Treatment and Management

Management of necrobiosis lipoidica is challenging, as no single therapy is uniformly effective and high-quality randomized controlled trials are lacking. Treatment goals include controlling disease progression, preventing ulceration, managing complications, and improving cosmetic appearance. A multidisciplinary approach involving dermatologists, endocrinologists, wound care specialists, and, when necessary, vascular surgeons and podiatrists is recommended.

Glycemic Optimization

Tight glycemic control is the cornerstone of management. While optimal glucose control may not reverse established lesions, it can reduce the risk of new lesions, slow progression, and decrease the likelihood of ulceration. Continuous glucose monitoring systems and insulin pump therapy have shown benefit in case reports and small series, likely by reducing glycemic variability and minimizing peaks in blood glucose. Target HbA1c levels should be individualized but generally aim for below 7.0% for most adults with diabetes, as recommended by the American Diabetes Association.

Topical and Intralesional Corticosteroids

Potent topical corticosteroids (e.g., clobetasol propionate 0.05% ointment) applied under occlusion or intralesional triamcinolone acetonide injections (5–10 mg/mL) are first-line treatments for active inflammatory plaques. These agents reduce the granulomatous infiltrate, suppress inflammation, and may slow plaque expansion. Intralesional injections are particularly useful for localized, thickened plaques. Prolonged use requires caution due to the risk of skin atrophy, which can exacerbate the underlying atrophic changes of necrobiosis lipoidica. Pulse therapy with intermittent application may mitigate this risk.

Phototherapy and Laser

Psoralen plus ultraviolet A (PUVA) and narrowband UVB have been used with variable success in small case series. PUVA, in particular, has been reported to improve plaque thickness and erythema, possibly through immunosuppressive and anti-inflammatory effects. More recently, pulsed dye laser (585–595 nm) targeting telangiectasias and the superficial vascular plexus has shown promise in improving cosmetic appearance and reducing erythema. Fractional carbon dioxide laser has been used to promote re-epithelialization of chronic ulcers and to stimulate dermal remodeling. A 2023 systematic review noted that laser therapy often leads to significant symptomatic and cosmetic improvement but is not curative, and multiple sessions are typically required.

Systemic Agents

For refractory, extensive, or rapidly progressive disease, systemic therapies may be considered. The evidence for most systemic agents is limited to case reports and small series, and treatment must be individualized based on disease severity, comorbidities, and patient preferences.

  • Pentoxifylline (400 mg three times daily) – improves microvascular blood flow by reducing blood viscosity and fibrinogen levels. It has been reported to reduce plaque size and promote ulcer healing in some patients. Side effects are generally mild and include gastrointestinal upset.
  • Systemic corticosteroids – oral prednisone or intravenous pulse methylprednisolone can induce rapid improvement in active inflammatory disease but are reserved for severe cases due to the risk of side effects, including worsening glycemic control, osteoporosis, and immunosuppression. Relapse is common upon tapering.
  • Antimalarials – hydroxychloroquine (200–400 mg daily) has been used off-label based on anecdotal evidence and small case series. It may be beneficial in patients with associated autoimmune features. Retinal toxicity screening is required.
  • Tumor necrosis factor inhibitors – case reports and small series suggest benefit from adalimumab (40 mg subcutaneously every 1–2 weeks) or infliximab (5 mg/kg intravenously at weeks 0, 2, and 6, then every 8 weeks), especially in ulcerated and refractory disease. These agents target the granulomatous inflammation and have shown promise in achieving complete or partial remission.
  • Mycophenolate mofetil (500–1500 mg twice daily) – reserved for severe, recalcitrant lesions. It acts as an immunosuppressant and has been reported to stabilize disease and promote ulcer healing. Gastrointestinal intolerance and increased infection risk are limiting factors.
  • Other agents – case reports have described benefit from cyclosporine, methotrexate, dapsone, and topical tacrolimus, though robust evidence is lacking.

Wound Care for Ulceration

When ulceration develops, standard chronic wound management principles apply: cleansing with normal saline or non-cytotoxic cleansers, debridement of necrotic tissue, moisture-retentive dressings (e.g., hydrocolloids, foams, alginates, or hydrogels), offloading of pressure, and infection control. Topical antimicrobials such as silver sulfadiazine or medical-grade honey may be used for colonized wounds. Systemic antibiotics should be reserved for clinically infected ulcers with surrounding cellulitis or signs of systemic infection. Negative-pressure wound therapy has been used to promote granulation tissue and reduce wound size in recalcitrant ulcers. Split-thickness skin grafting may be considered for large, non-healing ulcers after optimization of wound bed and vascular status. Topical growth factors such as platelet-derived growth factor (becaplermin) have been used off-label with variable success. Non-healing ulcers should be biopsied to rule out malignant transformation, particularly squamous cell carcinoma (Marjolin ulcer).

The American Diabetes Association offers guidelines on diabetic foot and leg ulcer care that are broadly applicable to necrobiosis lipoidica ulcers (see ADA Clinical Care Recommendations).

Surgical Options

Excision with split-thickness skin grafting may be considered for severe, localized, ulcerated disease that is refractory to medical therapy. However, recurrence at graft margins is common, and grafting carries a higher risk of failure on the poorly vascularized anterior shin. Pregraft optimization of blood flow through revascularization (if peripheral arterial disease is present) and meticulous wound bed preparation are essential for success. Excision should extend into healthy tissue to minimize the risk of recurrence. In selected cases, full-thickness skin grafts or local flaps may provide better outcomes than split-thickness grafts.

Complications

The most common and clinically significant complication is chronic ulceration, which can become secondarily infected with bacteria such as Staphylococcus aureus, Pseudomonas aeruginosa, or streptococci, leading to cellulitis, abscess formation, or even osteomyelitis if the underlying bone is exposed. In immunocompromised diabetic patients, particularly those with poor glycemic control or peripheral vascular disease, infection can be limb-threatening and may necessitate amputation in severe cases.

Squamous cell carcinoma arising within chronic ulcers of necrobiosis lipoidica (Marjolin ulcer) has been reported in rare cases, typically after many years of persistent ulceration. Any sudden change in ulcer appearance, such as exuberant granulation tissue, rolled or everted edges, friable tissue, or bleeding, should prompt immediate biopsy. Although the risk is low, the consequences of delayed diagnosis are severe, and periodic surveillance of chronic ulcers is warranted.

The psychosocial impact of necrobiosis lipoidica is significant and often underappreciated. The visible scarring, discoloration, and disfigurement on the lower legs can cause distress, reduced self-esteem, social withdrawal, and avoidance of activities that expose the legs (e.g., swimming, wearing shorts or skirts). Depression and anxiety are common, particularly in patients with extensive or ulcerated disease. Patient support groups and referral to a mental health professional may be beneficial.

Other complications include pain (from ulceration or neuropathy-associated burning), limited mobility due to pain or fear of trauma, and secondary lymphedema in cases of extensive lower leg involvement. The economic burden of chronic wound care, including dressings, clinic visits, and lost productivity, can also be substantial.

Prevention and Prognosis

Because necrobiosis lipoidica is strongly linked to microvascular damage, primary prevention focuses on risk factor modification. The most impactful interventions are strict glycemic control, smoking cessation, and aggressive management of hypertension and dyslipidemia. Regular skin inspection by both patient and clinician allows early detection of new lesions, and prompt initiation of treatment may prevent progression to ulceration. Patients should be counseled to protect their shins from minor trauma, to use emollients to maintain skin integrity, and to avoid tight-fitting clothing or footwear that could irritate the pretibial area.

Once established, necrobiosis lipoidica tends to run a chronic, progressive course with periods of relative stability. Spontaneous remission occurs in less than 20% of patients and is unpredictable. With appropriate care, including glycemic control, smoking cessation, and active treatment of inflammatory plaques, ulceration can often be prevented or managed effectively. The prognosis for life is not affected by the condition itself, but associated diabetic complications—particularly cardiovascular disease, nephropathy, and retinopathy—remain the primary determinants of overall outcomes. Patients with necrobiosis lipoidica should receive regular screening for these complications and aggressive management of cardiovascular risk factors.

For patients interested in lifestyle modifications and self-care strategies, the Diabetes UK information page provides practical advice on skin care, footwear, and when to seek medical attention.

Emerging Therapies and Research Directions

Several novel therapeutic approaches are under investigation for necrobiosis lipoidica. Biologic agents targeting specific inflammatory pathways, particularly TNF-α inhibitors and interleukin inhibitors, hold promise for refractory disease. Janus kinase (JAK) inhibitors, such as tofacitinib and ruxolitinib, are being explored for their ability to block the signaling pathways that drive granulomatous inflammation. Early case reports have shown encouraging results with topical ruxolitinib in reducing plaque thickness and inflammation.

Stem cell therapies, including mesenchymal stem cell injections and platelet-rich plasma, are being studied for their potential to promote tissue repair and modulate the immune response. Although still experimental, these approaches may offer future options for patients with severe, ulcerated disease that is unresponsive to conventional therapies.

Research into the molecular pathways of necrobiosis lipoidica, including the roles of AGEs, oxidative stress, and dysregulated angiogenesis, may ultimately lead to targeted therapies that address the underlying pathology at its source. Collaborative multicenter registries and clinical trials are urgently needed to establish evidence-based treatment protocols.

Conclusion

Necrobiosis lipoidica represents a distinctive cutaneous manifestation of diabetic microangiopathy and immune dysregulation. While its exact cause is not fully understood, the interplay of vascular damage, collagen glycation, and granulomatous inflammation is well recognized. Identifying modifiable risk factors—particularly poor glycemic control and smoking—is essential for both prevention and management. Early diagnosis, aggressive wound prevention, and a multidisciplinary approach involving dermatologists, endocrinologists, and wound care specialists can significantly improve patient quality of life. Although there is no cure, advances in laser therapy, biologic agents, and emerging treatments offer new hope for those with recalcitrant disease. Ongoing research into the molecular underpinnings of necrobiosis lipoidica will be critical for developing targeted therapies that can halt or reverse this chronic, disfiguring condition.